Background: Hyperphosphatemia is associated with significant pathophysiology in chronic kidney disease (CKD). Control of hyperphosphatemia in patients with stage 3 to 5D CKD is now regarded as a high priority. Objective: The primary purpose of this study was to perform an economic analysis of the newly available treatments sevelamer carbonate (SC) and lanthanum carbonate (LC) for the treatment of hyperphosphatemia in patients not on dialysis in Bulgaria. Methods: Both treatment options demonstrate equal efficacy in controlling hyperphosphatemia, as well as having a similar safety profile in regard to adverse effects. To differentiate between them, a cost-minimization analysis was performed. A time period of 4 years was chosen to perform a budget impact analysis. The robustness of the results was tested through sensitivity analysis using Tornado diagrams. Results: The estimated cost per patient per year with SC and LC would be €1441.75 and €1569.50, respectively, at the weighted average daily dose regimen of 4000 mg SC and 2000 mg LC, whereas the cost would be €2306.80 and €2354.25 for 6400 mg SC and 3000 mg LC, respectively. Expected cost savings (discounted) for the 4-year period of the analysis can reach between €1,363,601 and €2,727,201 at 4000 mg SC and 2000 mg LC dose regimen, whereas these can reach between €506,480 and €1,012,961 at 6400 mg SC and 3000 mg LC, respectively. Conclusions: The equal efficacy, similar adverse effect profile, and lower cost of SC when used for the treatment of hyperphosphatemia in patients with CKD not on dialysis should make it a preferred alternative.
Introduction
Chronic kidney disease (CKD), the progressive deterioration of kidney function, affects approximately 5% to 10% of the world's population [1] . It is most often caused by diabetes and hypertension, which together account for approximately two-third of CKD cases [2] . Similar numbers were reported for the Bulgarian population [3] . Compared with the general population, patients with CKD are at an increased risk of vascular calcification and mineral and bone disorders, leading to an increased risk of cardiovascular disease and mortality [1, 4, 5] . The sequel of mineral and bone disorders that accompany CKD has been termed chronic kidney disease-mineral and bone disorder. It is a systemic disorder of mineral and bone metabolism that occurs early in the pathophysiology of CKD, when loss of kidney function leads to progressive deterioration of the balance of minerals such as phosphorus and calcium, hormones, and other metabolites. Hyperphosphatemia or elevated phosphorus level in the blood is common in patients with CKD-mineral and bone disorder and independently and significantly contributes to morbidity and mortality in these patients [1, [4] [5] [6] [7] [8] . Decrease in the glomerular filtration rate below 59 ml/min is classified as mild to moderate loss of kidney function, whereas that below 29 ml/min is classified as severe according to Levin et al. [4] . Hyperphosphatemia leads to increased risk of calcification [5] , 70% increased risk of starting dialysis [7, 9] , a 30% greater risk of cardiovascular events [10, 11] , and increased risk of all-cause and cardiovascularrelated mortality [11] [12] [13] . Early and aggressive management of mineral imbalance, especially phosphorus, is a priority for patients with CKD and can achieve significant savings to health authorities by decreasing hospitalization rates within patients with higher serum phosphate. Managing serum phosphorus in CKD can lead to a decrease of 25% in the rate of cardiovascular events, 4 times lesser mortality,as the risk of starting dialysis and transplantation is reduced by 70% [7, 9, [14] [15] [16] [17] . The goal of phosphorus management is to maintain levels within the normal range of 2.5 to 4.5 mg/dL (0.81-1.45 mmol/L) according to the Kidney Disease: Improving Global Outcomes guideline [1] .
Phosphate binders are an essential component of managing hyperphosphatemia. Treatment with phosphate binders is independently associated with improved outcomes, including improved overall survival in patients with CKD [18] . Traditional binders such as those containing calcium or heavy metals are effective at reducing serum phosphorus, but they pose health risks associated with the accumulation of calcium or metal in the body [19] .
For part of the patients with CKD not on dialysis not eligible for calcium-or other metal-based phosphate binders because of vascular calcifications and toxicity, new alternatives were included in the positive list in Bulgaria, but these are still not marketed effectively in the country-Renvela 800 mg Â 180 tablets (sevelamer carbonate [SC] ; Genzyme, BV, The Netherlands) and Fosrenol 1000 mg Â 90 tablets (lanthanum carbonate [LC] ; Shire, Ltd., UK).
Renvela (SC) is a second-generation sevelamer (polymeric amine) compound with the same active moiety and mechanism of action as its predecessor Renagel (sevelamer hydrochloride [SH] ). SC differs from SH only in the replacement of chloride with carbonate as the counterion, which serves to increase buffering capacity and reduce the risk of gastrointestinal (GI) adverse events (AEs) and acidosis related to decreased serum bicarbonate concentrations. Such improvements in the chemical structure of SC may reduce the need for monitoring chloride and bicarbonate levels and may reduce the risk of acidosis [20] .
In three head-to-head randomized studies, SC and SH were shown to provide equivalent serum phosphorus control [21] [22] [23] . Given their structural similarities and equivalence in terms of serum phosphorus control and safety, it is reasonable to expect that SC will demonstrate an impact on other clinical outcomes (e.g., calcification and mortality) that is similar to that of SH.
Both SC and LC are significantly reducing serum phosphorus in patients with CKD. They are well tolerated, where the predominant AEs are of a GI nature with no serious events [21] [22] [23] [24] [25] [26] [27] [28] [29] .
In light of the increased incidence of CKD, constantly increasing health care spending, and cost-containment policies concerning medicines, there is a rising need for better allocation of scarce resources through informed decisions from the stakeholders.
We sought to investigate the evidence for efficacy and safety and to compare the direct cost of SC and LC in the treatment of hyperphosphatemia in patients with CKD not on dialysis in Bulgaria from the health authority perspective, that is, the National Health Insurance Fund (NHIF). Another study objective was to investigate the budget impact both products would have on entering the market effectively.
Methods

Search Strategy
A comprehensive search to identify all relevant studies was carried out. PubMed, Scopus, The Cochrane Library, NHC Evidence Search, and Google Scholar were searched (1998-August 2014). The following key words and phrases were used: sevelamer, lanthanum carbonate, clinical trial/study or efficacy or safety, hyperphosphatemia, cost-effectiveness, and costminimization.
Selection Criteria
Each potentially relevant study was independently assessed by two reviewers for inclusion in the study. For assessing the efficacy and safety, studies meeting the following criteria were eligible for inclusion: controlled clinical trials in which the efficacy and safety are examined in adults, with prevalence of white ethnicity (450%), with end-stage renal disease or patients with CKD not on dialysis treated with SC, SH, and LC compared with any phosphate binder or placebo.
Type of Analysis and Study Perspective
The two studies that concern patients not on dialysis allow for an indirect comparison [24, 28] , with SH being the common arm for the indirect comparison of SC and LC. The indirect comparison provides a similar AE profile and efficacy in controlling phosphate levels in patients with CKD not on dialysis, justifying a costminimization analysis (CMA).
As per approved label in Bulgaria, both SC and LC can be used for the treatment of hyperphosphatemia in patients with CKD not on dialysis, the cost of which is reimbursed at 75% by the NHIF. For this reason, the present study was carried out from the payer perspective.
Cost-Minimization Analysis
Both medicines are administered orally, with no considerable differences within the AEs' profiles, which can lead to hospitalization and/or increase in treatment cost. CMA was performed using the direct cost, that is, only unit cost per tablet of SC and LC incurred from the NHIF.
The prices were retrieved online from the officially published registries on the National Council for Pricing & Reimbursement's Web site [30] . An exchange rate of 1,95,583 BGN for €1 was used.
The daily/yearly costs of both therapies were calculated using the weighted average dose regimens, under which it was assumed that meaningful clinical outcomes will be achieved, that is, 4000 mg of SC versus 2000 mg of LC and 6400 mg of SC versus 3000 mg of LC, respectively [31, 32] .
Forecasting the Budget Impact to the NHIF
The budget impact was fulfilled for a 4-year period (2015-2018). We explored three scenarios in which the patient's allocation between the two treatment options SC and LC was 100:0, 50:50, and 0:100. The budget impact model is prevalence based. The target population was calculated by using the prevalence of CKD in Bulgaria [3] within the population according to the last census 2011 [33] .
Data regarding the prevalence considered for this analysis were obtained from the national representative epidemiological study of endocrine and kidney diseases in Bulgaria [3] .
Patients eligible for treatment are those in CKD stage 3 to 4 who cannot be treated with calcium-and other metal-based phosphate binders because of vascular calcification and toxicity.
Following the data published on the NHIF Web site, Intercontinental Marketing Services (IMS) data for the market share, and market trends when a new product is launched in Bulgaria, as well as the cost-containment rules limiting the number of eligible patients, we made several assumptions:
An increase of 0.2% per year, corresponding to the prevalence of CKD among the overall population within stage 3 to 4, as well as a 0.2% yearly increase in the number of patients eligible for treatment with SC and LC.
Having in mind the very restrictive insurance policy, it is also assumed that treatment will be received from 20% of the eligible patients in 2015 as for 2016, 2017 and 2018, the coverage will be 45%; 65% and 80% respectively.
The discount rate used was 3.5% as per National Institute of Health and Care Excellence recommendations [34] .
Sensitivity Analysis
A one-way sensitivity analysis (SA) was performed to examine the changes in costs when key cost driver variables were varied. The analysis includes the extreme values (Ϯ30%) of the prevalence of stage 3 to 4 CKD in patients and the unit costs to whet the attention to those of them with greatest effects on the results of this analysis. The SA was performed with discounted costs only. The results were presented under Tornado diagrams to provide a quick overview and to represent the related importance of the key cost driver variables.
Results
The efficacy and safety results of the clinical trials have been published in detail elsewhere [21] [22] [23] [24] [25] [26] [27] [28] [29] 35] , and the relevant clinical outcomes are summarized in Tables 1 and 2 .
We found four clinical trials in which the efficacy and safety of SC were investigated in patients with CKD on dialysis [21] [22] [23] [24] [25] and one clinical trial in patients not on dialysis [24] .
Three clinical trials in which the efficacy and safety of LC were investigated in patients with CKD on dialysis were found [26] [27] [28] [29] and one clinical trial in patients not on dialysis [28] .
Only one clinical trial was identified in which SH was directly compared with LC in a head-to-head study in patients on dialysis [35] .
All three studies [21] [22] [23] in which the efficacy and safety of SC versus SH are compared in head-to-head trials in patients on dialysis confirm that both have equal efficacy in lowering serum phosphorus levels because the results are statistically significant (P o 0.001). Safety profiles were shown to be similar. AEs mainly had a GI origin, with no serious AEs arising from both treatments, because no clinically significant changes were observed for safety parameters.
In the study conducted by Ketteler et al. [24] , SC shows efficacy in lowering serum phosphorus levels in patients with CKD not on dialysis (P o 0.001), AEs were predominately mild to moderate and were related to the GI tract in nature, and there were no serious AEs or deaths occurring during the study that were considered to be related to treatment.
LC also shows efficacy in the treatment of hyperphosphatemia in patients on dialysis [26, 27, 29] , with statistically significant results. The AEs predominantly had their origin in the GI tract and had mild to moderate severity.
In the study of Sprague et al. [28] , LC shows efficacy in treating hypophosphatemia in patients with CKD not on dialysis, with statistically significant difference (P o 0.02).
We found only one head-to-head clinical trial in which SH was compared directly with LC in patients on dialysis. In this open-label, randomized, crossover study (N ¼ 182), patients with levels of serum phosphorus and calcium greater than 6.0 mg/dL and 8.4 mg/dL, respectively, were randomized to receive either LC or SH following washout. After 4 weeks of treatment and a second washout period, patients switched to the alternative treatment for 4 weeks. At the end of the two study periods, serum phosphorus levels were reduced in patients treated with LC by 1.7 Ϯ 0.1 mg/dL versus 1.4 Ϯ 0.1 mg/dL in patients treated by SH. The difference of 0.3 mg/dL greater reduction observed with LC after 4 weeks of treatment was not statistically significant (P ¼ 0.133). In a predefined secondary analysis of patients who completed 4 weeks of treatment with both binders, the difference reached statistical significance (mean difference -0.5 mg/dL; P ¼ 0.007). Serum calcium level was increased with LC (0.1 Ϯ 0.1 mg/dL) and decreased with SH (-0.1 Ϯ 0.1 mg/dL; significant difference between treatments, P ¼ 0.02), and intact parathyroid hormone levels were increased by a similar degree with both therapies (LC 296.1 Ϯ 16.5 pg/mL; SH 286.9 Ϯ 16.4 pg/mL). Study withdrawal was not different among the LC (n ¼ 25) and SH (n ¼ 23) treatment groups, and GI-related AEs were observed in both treatment groups (18.2% and 22.3%, respectively).
Cost-Minimization Analysis
The unit cost (per tablet) used in the analysis was €0.79 for SC and €2.15 for LC, calculated on the basis of the retail prices reimbursed by the NHIF.
Because SC and LC have different potency in decreasing phosphorus levels, their effects depend on the applied dose, and it is important to define the relative dose for cost estimations to be precise and to address what happens in the real settings. Based on the head-to-head trial by Sprague et. al 2009 [35] , approved labels, and the recently published study of the dose relativity of SC versus LC [36] , the equi-effective doses reported as similar are 2.1:1 (SC:LC).
Having in mind the equi-effective dose ratio and approved labels, it was assumed that meaningful clinical outcomes will be achieved with dose regimens of 4000 mg of SC versus 2000 mg of LC and 6400 mg of SC versus 3000 mg of LC.
The data summarized in Table 3 represent the daily and yearly costs incurred by the NHIF per patient treated with SC and LC, respectively, and the expected cost savings within proposed dose regimens.
Therefore, treatment with SC instead of LC will result in a cost saving of €127.75 versus €47.45 per patient per year, respectively.
Forecasting the Budget Impact to the NHIF
The results of eligible patients for treatment with SC and LC in Bulgaria are presented in Table 4 .
The results of the budget impact are presented in Tables 5  and 6 . Table 5 presents the results of cost estimates and the savings concerning the weighted average dose regimens of 4000 mg of SC versus 2000 mg of LC.
Expected cost saving can reach as much as €1,507,769 (€1,363,601 discounted at 3.5%) at the patient allocation of SC 50%:LC 50% and €3,015,539 (€2,727,201) at the patient allocation of SC 100% versus LC 100%, respectively. Table 6 presents the results of cost estimates and savings concerning the weighted average dose regimens of 6400 mg of SC versus 3000 mg of LC.
Expected cost saving to the NHIF can reach as much as €560,029 (€506,480) at the patient allocation of SC 50%:LC 50% and €1,120,057 (€1,012,961) at the patient allocation of SC 100% versus LC 100%, respectively.
Sensitivity Analysis
The results of the one-way SA (discounted) clearly show that the major cost drivers in the treatment of hyperphosphatemia in patients with CKD not on dialysis are the unit costs of SC and LC. The results were confirmed when the same values for the prevalence of CKD and stage 3 to 4 of CKD and the unit costs of SC and LC within 6400 mg SC versus 3000 mg LC dose regimens were used. At the study end point, the mean difference in serum phosphorus levels between the LC and placebo treatment arms was 1.91 mg/dL (0.62 mmol/L) (P o 0.0001). Calcium Â phosphorus product (P o 0.0001) and serum PTH levels (P o 0.01) were also significantly lower with LC vs. placebo AEs were experienced by 47.4% of the patients in the LC group compared with 61.0% in the placebo group. These were mainly gastrointestinal in nature, with nausea (LC and placebo 9.0% and 9.8%, respectively) and vomiting (6.4% and 2.4%, respectively) being the most common. In total, 19.3% of the AEs experienced in the LC group were considered related to treatment, compared with 16.7% in the placebo group Most AEs were of mild or moderate severity in both LC-and calcium carbonate-treated patients during the titration and maintenance phases; o10% of the AEs were classified as severe. GI AEs were reported most frequently and occurred with similar frequency in the two treatment groups: Constipation: LC 6% vs. placebo 6.7%
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The incidence of drug-related AEs was similar between placebo-and LC-treated patients AEs were related mainly to the GI tract (e.g., nausea and vomiting) Diarrhea: 12.6% vs. 9.7% Nausea: 15.9% vs. 12.7% Vomiting: 18.4% vs. 11.2%
AEs were predominately mild to moderate and were related to the GI tract in nature Treatment-related AEs occurred in 39% of the patients treated with LC and 44% of the placebo group AE, adverse event; CKD, chronic kidney disease; GI, gastrointestinal; LC, lanthanum carbonate; PTH, parathyroid hormone.
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Discussion SC and LC are widely used and are effective and safe for the treatment of hyperphosphatemia. Despite of the limited utilization, we choose a CMA on the basis of results from a head-tohead trial [30] and because of the lack of a statistically significant difference between both treatment options in terms of efficacy and safety. However, it should be noted that there were a couple of limitations, which should be taken into consideration:
Currently, there is just one available clinical trial reflecting the study selection criteria that directly compares SH versus LC because patients explored were in end-stage renal disease but not ones not on dialysis.
CMA compares only the direct costs under the assumption that the clinical outcomes and AE profiles of both are equivalent.
Some researchers could consider the use of CMA as a limitation, but for health care systems with very limited budgets it is important for such analysis to be performed. Bulgaria has one of the lowest expenditures as part of GDP for health care within European Union, 4.8% versus the average for EU of 7.5% from the gross domestic product. Statistical information published on the Eurostat Web site clearly shows that the health care expenditure in Bulgaria for the period 2002 to 2012 has decreased from 5.3% to 4.8% [37] and for 2014 it was 4.85% [38] . This shows that stringent control over the expenditures is imposed and choice of the less costly but equally effective alternatives will benefit the patients.
The expenses for CKD and dialysis treatment are about €37 million per year. Expenses are steady within the local NHIF budget for last 3 years, with no change for 2015 [38] .
The cost difference between both regimens was only due to the lower registered price for SC. Our interest in that study was provoked by the inclusion of both products in the positive list.
Despite the fact that SC and LC have registered prices, both products were not marketed during the study period. That is why we developed three versions of the budget impact analysis, assuming the market shares to be 100%/0%, 50%/50%, and 0%/100%.
The percentage of eligible patients covered by the NHIF, that is, 20% in 2015 to 80% in 2018, was assumed on the basis of the current market trends and prescription criteria for the treatment of CKD [39] . NHIF, National Health Insurance Fund. * Where the dose is not exactly within the equi-effective dose of 2.1:1, it was set to the closest number of tablets. It is necessary to note that considering the fact that eligible patients are in stage 3 to 4 of CKD, most will be on low-protein diet and with phosphorus levels close to the recommended ones, and so the most suitable and preferred regimen seems to be 4000 mg SC versus 2000 mg LC.
The results in this analysis are derived under the assumption that the dose relativity of SC:LC is 2.1:1 [36] . In two other studies, the dose relativity was estimated to be 2.8:1 and 2.7:1, respectively [40, 41] , but the results in both were derived by using indirect comparison of trials that are widely variable clinically, which made the calculation of the equi-effective dose uncertain.
The SA results show that the unit cost outweigh the CKD prevalence. From both tornado diagrams, it is obvious that the 
variation in the unit cost of SC and LC has a major impact on the change in the savings. The second conclusion that could be drawn from the SA is that the change in the savings depends on the prevalence of the disease in stage 3 to 4. This has a higher impact in the change in the savings than does the variation in the prevalence of CKD at all. In the context of the scarce resources available for health care, the aging population, the increased prevalence of chronic diseases, the cost-containment policies, and the efforts of the government to provide treatment to a wider group of patients, it is becoming more important that decision makers take into consideration data from such analyses. This will add more reasoning to informed decision making about the usage of given treatment options and their economic implications.
This analysis represents the first study to evaluate the economic impact of drug selection in the case of treatment of 
Conclusions
This economic analysis has shown that SC is associated with lower costs compared with LC when used for the treatment of hyperphosphatemia in patients with CKD not on dialysis.
For decision makers with limited budgets, the treatment with SC regimen therefore represents an efficient use of resources for patients with CKD not on dialysis in Bulgaria.
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